Programme |
7è Symposium of de la Fondation André-Delambre
Sclérose latérale amyotrophic: Causes et perspectives thérapeutiques
|
 Vendredi 23 septembre 2011
|
 |
| |
|
| 8:30-8:40 |
Mot de bienvenue |
Génétiques and mécanismes
President: Jean-Pierre Julien (Centre de recherche du CHUQ, Université Laval) |
| 8:40-9:10 |
Robert Brown, (University of Massachusetts School of Medicine)
ALS causes |
| 9:10–9:40 |
Teepu Siddique (Northwestern University)
FUS and optineurin in ALS |
| 9:40-10:10 |
Wim Robberecht (VIB Vesalius Research Center, Leuven)
Zebrafish as a model to identify modifiers of ALS |
| 10:10-10:30 |
|
Président: Richard Robitaille (Université de Montréal) |
| 10:30-11:00 |
Stéphanie Millecamps (INSERM, Hôpital de la Salpêtriere)
Optineurin mutations in ALS |
| 11:00-11:30 |
Daryl Bosco (University of Massachusetts School of Medicine)
Stress granules and FUS |
| 11:30-12:00 |
Clotilde Lagier-Tourenne (University of California at San Diego)
TDP-43 and FUS in ALS: identifying the basis for neuronal vulnerability |
| 12:00-1:30 |
Pause midi et visite des affiches
|
Neuroinflammation
Président: Jasna Kriz (Université Laval)
|
| 13:30-14:00 |
Michal Schwartz (The Weizmann Institute of Science, Israel)
Immune pathology in ALS: A co-morbidity factor and a potential target for intervention? |
| 14:00-14:30 |
Stanley Appel (Methodist Neurological Institute, Houston)
Immunomodulation as a Potential Pathway to Therapy in Amyotrophic Lateral Sclerosis |
| 14:30-15:00 |
Jean-Pierre Julien ((Université Laval)
NFκB as therapeutic target in new TDP-43 transgenic mouse models |
| 15:00-15:20 |
Pause café |
Thérapies expérimentales and tests cliniques
Président: Angela Genge (Montreal Neurological Institute, McGill University) |
| 15:20-15:50 |
Jeffrey Rothstein (Johns Hopkins School of Medicine)
Glia and oligodendroglia as targets |
| 15:50-16:20 |
Clive Svendsen (Cedars-Sinai Regenerative Medicine Institute, LA)
Human stem cells increase respiratory output in the SOD1 G93A rat model of ALS |
| 16:20-16:50 |
Jonathan Glass (Emory University)
First in human trial of spinal cord stem cell injections for ALS |
| 16:50 |
Réception vin et fromage |
| |
| |
Samedi 24 septembre 2011 |
|
| |
Agrégats de protéines et toxicité
Chair:
Denise Figlewicz (ALS Society of Canada) |
| 8:30 - 9:00 |
David Borchelt (McKnight Brain Institute, Florida)
SOD1 misfolding and toxicity |
| 9:00 - 9:30 |
Neil Cashman (University of British Columbia)
Propagated misfolding of SOD1 is central to the pathogenesis of ALS |
| 9:30 - 10:00 |
Piera Pasinelli ((Thomas Jefferson University, Philadelphia)
Studies of mitochondrial toxicity in FALS and SALS |
| 10:00 - 10:30 |
Pause café |
|
| 10:30 – 11:00 |
Milos Pekny (University of Gothenburg)
Reactive gliosis |
| 11:00 – 11:30 |
Jasna Kriz (Centre de recherche du CHUQ, Université Laval)
Live imaging of pre-onset ALS in mouse models |
| 11:30 – 12:00 |
Reinhard Dengler (Hannover Medical School, Germany)
Imaging in ALS |
| 12:00 - 13:00 |
Pause midi et visite des affiches |
Mécanismes
Président: Angela Genge (Montreal Neurological Institute, McGill University) |
| 13:30 - 14:00 |
Victor Rafuse (Dalhousie University)
Mouse iPS-cell derived motoneurons |
| 14:00 - 14:30 |
Gary Armstrong (Université de Montréal)
Defective neuromuscular transmission in zebrafish expressing human TARDBP mutant |
| 14:00 - 15:00 |
John Turnbull (McMaster University)
Potential primary cilial abnormality in ALS |
| 15:00 - 15:20 |
Pause café |
| |
|
Président: Jean-Pierre Julien (Université Laval)
|
| |
|
| 15:20 - 15:50 |
Janice Robertson (University of Toronto)
TDP-43 and it's splice variants in ALS |
| 15:50 - 16:20 |
Ludo Van den Bosch (VIB Vesalius Research Center, Leuven)
HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease |
| 16:20 - 16:50 |
Nicolas Dupré
The wide heterogeneity of motor neuron diseases |
| 16:50 |
Mot de la fin |
| |
|
